Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Analysis Plan



    The supplied evidence contains no Hokkaido Study data on PFOS/PFOA/PFNA/PFDA child outcomes or confounding checks, so the query cannot be evaluated; the closest relevant source only traces maternal PFAS to placental/cord burdens across trimesters, a different population and question.


     Long Analysis Plan



    Requested Evidence Is Missing

    None of the supplied claim-level records include the Hokkaido Study (a Japanese birth cohort), child neurodevelopmental or health outcomes, or any confounder-adjustment analyses (e.g., maternal smoking, income, parity, breastfeeding). What is supplied instead: in vitro PFOS/PFOA/PFNA cytotoxicity in H4/TLT cells; PFAS class-based regulation commentary; a Maine beef-cattle toxicokinetic model; mouse bile-acid cholestasis from PFNA; marine-mammal liver PFAS; U.S. breast-milk PFAS trends; trimester-specific maternal-placental-cord PFAS transfer; and an ambient PFAS analytical method.

    The nearest human-exposure record shows transplacental transfer efficiency rising across pregnancy (e.g., PFNA 43.4%β†’72.1%; PFOS 27.9%β†’36.1%) but reports no child outcomes and no confounding checks .

    To battle-test the actual claim, please supply the Hokkaido Study full text (e.g., Kishi et al. birth-cohort papers) so effect estimates, covariate sets, sensitivity analyses, and exposure windows can be evaluated.



    Feedback:    

    Updated: October 26, 2026



     Top Data Sources ExportMCP



     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT